Company
Endogenex
Signaling a new era in T2D therapy™
Also known as Endogenex, Inc
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Endogenex, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Endogenex, in partnership with Mayo Clinic, was founded to revolutionize the therapeutic approach to type 2 diabetes (T2D). Endogenex’s innovations leverage energy delivery in the small intestine (duodenum) to reset the body’s metabolic signaling system, harnessing its’ natural regeneration capabilities to restore metabolic function.
Funding snapshot
- Total raised
- $122MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $69.6M2024-06-13
Funding rounds
- Round, 2024
- $69.6M2024-06-13, SEC form D sold, 11 investors
- Round, 2023
- $18.3M2023-10-11, SEC form D sold, 9 investors
- Round, 2023
- $9.2M2023-02-17, SEC form D sold, 7 investors
- Round, 2021
- $12M2021-04-15, SEC form D sold, 7 investors
- Round, 2018
- $12.8M2018-11-30, SEC form D sold, 6 investors
- Round, 2018
- $140K2018-01-31, SEC form D sold, 6 investors
About the company
- Status notes
- The Endogenex system is investigational and under evaluation in clinical studies
Products
- Hardware
- Endogenex system
- Web
- Endogenex System
Loading relationship preview